Back to Search Start Over

Automated CD34+ cell isolation of peripheral blood stem cell apheresis product.

Authors :
SPOHN, GABRIELE
WIERCINSKA, ELIZA
BUNOS, MILICA
HÜMMER, CHRISTIANE
WINGENFELD, EVA
SORG, NADINE
POPPE, CAROLIN
SEIFRIED, ERHARD
BÖNIG, HALVARD
KARPOVA, DARJA
HUPPERT, VOLKER
STUTH, JULIANE
RECK, KRISTINA
ESSL, MIKE
Source :
Cytotherapy (Elsevier Inc.). Oct2015, Vol. 17 Issue 10, p1465-1471. 7p.
Publication Year :
2015

Abstract

Background aims. Immunomagnetic enrichment of CD34+ hematopoietic "stem" cells (HSCs) using paramagnetic nanobead coupled CD34 antibody and immunomagnetic extraction with the CliniMACS plus system is the standard approach to generating T-cell-depleted stem cell grafts. Their clinical beneficence in selected indications is established. Even though CD34+ selected grafts are typically given in the context of a severely immunosuppressive conditioning with anti-thymocyte globulin or similar, the degree of T-cell depletion appears to affect clinical outcomes and thus in addition to CD34 cell recovery, the degree of T-cell depletion critically describes process quality. An automatic immunomagnetic cell processing system, CliniMACS Prodigy, including a protocol for fully automatic CD34+ cell selection from apheresis products, was recently developed. We performed a formal process validation to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products. Methods. Granulocyte-colony stimulating factor--mobilized healthy-donor apheresis products were subjected to CD34+ cell selection using Prodigy with clinical reagents and consumables and advanced beta versions of the CD34 selection software. Target and non-target cells were enumerated using sensitive flow cytometry platforms. Results. Nine successful clinical-scale CD34+ cell selections were performed. Beyond setup, no operator intervention was required. Prodigy recovered 74 ± 13% of target cells with a viability of 99.9 ± 0.05%. Per 5 x 10E6 CD34+ cells, which we consider a per-kilogram dose of HSCs, products contained 17 ± 3 x 10E3 T cells and 78 ± 22 x 10E3 B cells. Conclusions. The process for CD34 selection with Prodigy is robust and labor-saving but not time-saving. Compared with clinical CD34+ selected products concurrently generated with the predecessor technology, product properties, importantly including CD34+ cell recovery and T-cell contents, were not significantly different. The automatic system is suitable for routine clinical application. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14653249
Volume :
17
Issue :
10
Database :
Academic Search Index
Journal :
Cytotherapy (Elsevier Inc.)
Publication Type :
Academic Journal
Accession number :
110011111
Full Text :
https://doi.org/10.1016/j.jcyt.2015.04.005